Waltham Startup Focuses on Engineering Antibodies As a Bridge to COVID-19 Vaccine
Jul 16, 2020 | The Boston Globe
"On Thursday, a Lebanon, N.H., firm that has engineered antibodies for more than 65 pharmaceutical companies, said it has spun out a Waltham company to focus on making monoclonal antibodies that would be injected into people twice a year to protect them against this coronavirus and several related coronaviruses," reports The Boston Globe.
"The new firm, Adagio Therapeutics, was launched with $50 million in venture capital and hopes to begin testing the antibodies on healthy humans by the end of the year.
"Tillman Gerngross, a Dartmouth bioengineering professor who is chief executive and cofounder of Adagio and its parent company, Adimab, said he believes that SARS-CoV-2, the virus that causes COVID-19, won’t be the last coronavirus to leap from animals to humans.
“'You can sit here now and take the position that this is never going to happen again,' said Gerngross. 'We take the opposite position. It is going to emerge again.'”